Abstract
Colorectal cancer is the second most common cause of cancer-related deaths in Australia. The median survival of metastatic colorectal cancer remains poor, but novel targeted therapies offer promise in improving patient outcomes. However, it is vital to identify which patients with metastatic colorectal cancer will benefit from targeted therapy. Predictive biomarkers offer significant benefit by refining the treatment population to a subgroup that has a greater prospect of benefit from therapy. This provides efficacy benefits, but also minimizes the overall toxicity and cost of treatment. In this review we examine current knowledge regarding predictive biomarkers for targeted agents in metastatic colorectal cancer, with a particular focus on emerging biomarkers such as oncogenic mutations. We also highlight issues that require further exploration in the quest for personalized therapy in metastatic colorectal cancer.
| Original language | English |
|---|---|
| Pages (from-to) | 208-217 |
| Number of pages | 10 |
| Journal | Asia-Pacific Journal of Clinical Oncology |
| Volume | 4 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - 2008 |
| Externally published | Yes |
Keywords
- Angiogenesis inhibitor
- Colorectal cancer
- Drug response biomarkers
- Epidermal growth factor receptor
- K-ras oncogene
Cite this
}
Predicting the response to targeted therapy in metastatic colorectal cancer. / Azad, Arun; Tebbutt, Niall C.
In: Asia-Pacific Journal of Clinical Oncology, Vol. 4, No. 4, 2008, p. 208-217.Research output: Contribution to journal › Review Article › Research › peer-review
TY - JOUR
T1 - Predicting the response to targeted therapy in metastatic colorectal cancer
AU - Azad, Arun
AU - Tebbutt, Niall C.
PY - 2008
Y1 - 2008
N2 - Colorectal cancer is the second most common cause of cancer-related deaths in Australia. The median survival of metastatic colorectal cancer remains poor, but novel targeted therapies offer promise in improving patient outcomes. However, it is vital to identify which patients with metastatic colorectal cancer will benefit from targeted therapy. Predictive biomarkers offer significant benefit by refining the treatment population to a subgroup that has a greater prospect of benefit from therapy. This provides efficacy benefits, but also minimizes the overall toxicity and cost of treatment. In this review we examine current knowledge regarding predictive biomarkers for targeted agents in metastatic colorectal cancer, with a particular focus on emerging biomarkers such as oncogenic mutations. We also highlight issues that require further exploration in the quest for personalized therapy in metastatic colorectal cancer.
AB - Colorectal cancer is the second most common cause of cancer-related deaths in Australia. The median survival of metastatic colorectal cancer remains poor, but novel targeted therapies offer promise in improving patient outcomes. However, it is vital to identify which patients with metastatic colorectal cancer will benefit from targeted therapy. Predictive biomarkers offer significant benefit by refining the treatment population to a subgroup that has a greater prospect of benefit from therapy. This provides efficacy benefits, but also minimizes the overall toxicity and cost of treatment. In this review we examine current knowledge regarding predictive biomarkers for targeted agents in metastatic colorectal cancer, with a particular focus on emerging biomarkers such as oncogenic mutations. We also highlight issues that require further exploration in the quest for personalized therapy in metastatic colorectal cancer.
KW - Angiogenesis inhibitor
KW - Colorectal cancer
KW - Drug response biomarkers
KW - Epidermal growth factor receptor
KW - K-ras oncogene
UR - http://www.scopus.com/inward/record.url?scp=57849138484&partnerID=8YFLogxK
U2 - 10.1111/j.1743-7563.2008.00215.x
DO - 10.1111/j.1743-7563.2008.00215.x
M3 - Review Article
VL - 4
SP - 208
EP - 217
JO - Asia-Pacific Journal of Clinical Oncology
JF - Asia-Pacific Journal of Clinical Oncology
SN - 1743-7555
IS - 4
ER -